IN BRIEF: Omega Diagnostics Completes AbC-19 Self-Test Usability Study

Omega Diagnostics Group PLC - medical diagnostics company - Says the self-test usability study ...

Alliance News 7 September, 2020 | 2:50PM
Email Form

Omega Diagnostics Group PLC - medical diagnostics company - Says the self-test usability study for the UK Rapid Test Consortium's Covid-19 lateral flow antibody test has concluded. The study was performed by Ulster University using 2,000 volunteers and completed over the weekend. The AbC-19 rapid test has already been CE-Marked for professional use. Omega said it remains on track to have production capacity in place this month to produce an initial 100,000 AbC-19 rapid test per week, scaling up to 200,000 tests per week capacity in October. "We're very pleased that the self-test usability study has completed and that we are progressing towards our goal of MHRA approval for self-test home use. We cannot give a timescale for when this might be achieved but we look forward to updating shareholders on further developments," said Chief Executive Colin King.

Current stock price: 67.59 pence

Year-to-date change: multiplied from 14.22p

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Omega Diagnostics Group PLC 74.00 GBX -20.00 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies